⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2024Japanese Journal of Pharmacoepidemiology/Yakuzai ekigakuOpen Access

Risk of Hypocalcemia with Denosumab in Patients with Rheumatoid Arthritis Based on Data From MID-NET® in Japan

Kei Sagawa Atsushi Takita Takuyuki Matsumoto Hirokazu Tanabe

View Full Paper

Ask AI

Bookmark

Share

Abstract

Objective: To evaluate the real-world risk of hypocalcemia in Japanese patients with rheumatoid arthritis (RA) receiving disease-modifying antirheumatic drugs (DMARDs) newly initiated on denosumab (PRALIA®) versus those receiving DMARDs alone.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sagawa et al. (2024) studied this question.

synapsesocial.com/papers/6a8bb70fb676b7d1a2fb7535 https://doi.org/10.3820/jjpe.29.e3

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Denosumab in Postmenopausal Women with Low Bone Mineral DensityRCT · 2006 · 1,226 citations
2Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women&rsquo;s health practiceReview · 2016 · 15 citations
3Denosumab for the treatment of osteoporosisReview · 2017 · 32 citations
4Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trialRCT · 2008 · 576 citations
5Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trialRCT · 2019 · 140 citations

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review2019
Hypocalcaemia in patients with metastatic bone disease treated with denosumab2015
<i>Clinical Trials Express:</i>Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)2014
The Current State of Regulatory Post-Marketing Studies in Japan: A Questionnaire Survey on Good Post-Marketing Study PracticeJapanese Journal of Pharmacoepidemiology/Yakuzai ekigaku · 2026
Emulating Target Trials to Address Immortal Time: Sequential Trial Emulation and the Clone-Censor-Weight MethodJapanese Journal of Pharmacoepidemiology/Yakuzai ekigaku · 2026

More from Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku

More from Daiichi-Sankyo (Japan)